Regulatory News
Wednesday, December 7, 2016
BRIEF-Aerie Pharma completes enrollment of mercury 2 phase 3 registration trial of roclatan
* Aerie pharmaceuticals completes enrollment of mercury 2
phase 3 registration trial of roclatan(tm)
(netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment